Rational drug sequencing of paclitaxel, gemcitabine and carboplatin in patients with untreated stage IV and select stage IIIB non-small cell lung cancer

Lung Cancer

Volumn 53, Issue 2, 2006, Pages 177-181

  Sovak, Mika A ^a   Lutzker, Stuart ^a   Zheng, Ling ^a   Guensch, Lisa ^a   Joyce, Margaret ^a   Schwartz, Susan ^a   Wu, Yujun ^b   Aisner, Joseph ^a  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Advanced disease; Non small cell lung cancer; Novel chemotherapy regimens; Phase II trial

Indexed keywords

CARBOPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; GEMCITABINE; GRANISETRON; PACLITAXEL; RANITIDINE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; FATIGUE; FEMALE; HEART INFARCTION; HEMATOLOGIC DISEASE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PREMEDICATION; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PLEURAL EFFUSION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33745757141     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2006.05.014     Document Type: Article

References (28)

1. WHO. Cancer-fact sheets (2006), WHO
2. Georgoulias V., Ardavanis A., Agelidou A., Agelidou M., Chandrinos V., Tsaroucha E., et al. Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter phase III trial. J Clin Oncol 22 (2004) 2602-2609
3. Lilenbaum R.C., Herndon II J.E., List M.A., Desch C., Watson D.M., Miller A.A., et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol 23 (2005) 190-196
4. Sederholm C. Gemcitabine versus gemcitabine/carboplatin in advanced non-small cell lung cancer: preliminary findings in a phase III trial of the Swedish Lung Cancer Study Group. Semin Oncol 29 (2002) 50-54
5. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311 (1995) 899-909
6. Kelly K., Crowley J., Bunn Jr. P.A., Presant C.A., Grevstad P.K., Moinpour C.M., et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 19 (2001) 3210-3218
7. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2002) 92-98
8. Le Chevalier T., Scagliotti G., Natale R., Danson S., Rosell R., Stahel R., et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 47 (2005) 69-80
9. Wozniak A.J., Crowley J.J., Balcerzak S.P., Weiss G.R., Spiridonidis C.H., Baker L.H., et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 16 (1998) 2459-2465
10. D'Addario G., Pintilie M., Leighl N.B., Feld R., Cerny T., and Shepherd F.A. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 23 (2005) 2926-2936
11. Favaretto A., Ceresoli G.L., Paccagnella A., Barbieri F., Bearz A., Ghiotto C., et al. Paclitaxel and carboplatin in combination with gemcitabine: a phase I-II trial in patients with advanced non-small-cell lung cancer. Gruppo Studio Tumori Polmonari Veneto (GSTPV). Ann Oncol 11 (2000) 1421-1426
12. Thompson D., Hainsworth J., Scullin D., Kalman L., Butts J., Urba W., et al. Paclitaxel-carboplatin alone or with gemcitabine or vinorelbine for stage IV and IIIB non-small cell lung cancer: longterm follow-up. Proceedings of the 2000 ASCO annual meeting (2000)
13. Alberola V., Camps C., Provencio M., Isla D., Rosell R., Vadell C., et al. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol 21 (2003) 3207-3213
14. Comella P., Frasci G., Panza N., Manzione L., De Cataldis G., Cioffi R., et al. Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group. J Clin Oncol 18 (2000) 1451-1457
15. DiPaola R.S., Rubin E., Toppmeyer D., Eid J., Butzbach D., Dvorzhinski D., et al. Gemcitabine combined with sequential paclitaxel and carboplatin in patients with urothelial cancers and other advanced malignancies. Med Sci Monit 9 (2003) PI5-PI11
16. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
17. Lin Y., and Shih W.J. Adaptive two-stage designs for single-arm phase IIA cancer clinical trials. Biometrics 60 (2004) 482-490
18. Tempero M., Plunkett W., Ruiz Van Haperen V., Hainsworth J., Hochster H., Lenzi R., et al. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21 (2003) 3402-3408
19. Ceribelli A., Gridelli C., De Marinis F., Fabi A., Gamucci T., Cortesi E., et al. Prolonged gemcitabine infusion in advanced non-small cell lung carcinoma: a randomized phase II study of two different schedules in combination with cisplatin. Cancer 98 (2003) 337-343
20. Tibaldi C., Bernardini I., Chella A., Russo F., Toma G., Tempestini F., et al. Prolonged gemcitabine infusion in advanced non-small-cell lung cancer with stable disease after gemcitabine 30-min infusion. Lung Cancer 51 (2006) 217-223
21. Zwitter M., Kovac V., Smrdel U., Kocijancic I., Segedin B., and Vrankar M. Phase I-II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer. Anticancer Drugs 16 (2005) 1129-1134
22. Motwani M., Rizzo C., Sirotnak F., She Y., and Schwartz G.K. Flavopiridol enhances the effect of docetaxel in vitro and in vivo in human gastric cancer cells. Mol Cancer Ther 2 (2003) 549-555
23. Peters G.J., Bergman A.M., Ruiz van Haperen V.W., Veerman G., Kuiper C.M., and Braakhuis B.J. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 22 (1995) 72-79
24. Rose P.G., Mossbruger K., Fusco N., Smrekar M., Eaton S., and Rodriguez M. Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma. Gynecol Oncol 88 (2003) 17-21
25. Edelman M.J., Gandara D.R., Lau D.H., Lara P., Lauder I.J., and Tracy D. Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel. Cancer 92 (2001) 146-152
26. Edelman M.J., Clark J.I., Chansky K., Albain K., Bhoopalam N., Weiss G.R., et al. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel. Clin Cancer Res 10 (2004) 5022-5026
27. Abbruzzese J.L., Grunewald R., Weeks E.A., Gravel D., Adams T., Nowak B., et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9 (1991) 491-498
28. Grunewald R., Kantarjian H., Keating M.J., Abbruzzese J., Tarassoff P., and Plunkett W. Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (Gemcitabine) administration in leukemia. Cancer Res 50 (1990) 6823-6826